COL18A1 and neoplasm: Continuous intraperitoneally administration of endostatin results in more effective tumor suppression compared with bolus administration in this model.[19] A phase I study of pharmacokinetic in patients with advanced cancer[20] showed that 4-week continuous intravenous infusion of recombinant human (rh)-endostatin was safe.